Research programme: CCR5 antagonists - Kemia
Latest Information Update: 26 Feb 2008
At a glance
- Originator Kemia
- Mechanism of Action CCR5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 22 Jun 2005 Preclinical trials in HIV infections treatment in USA (PO)
- 22 Jun 2005 Kémia's CCR5 antagonists programme is available for partnering (http://www.kemia.com)